Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
Third-Party Tested Batch & Lot Tracking Free Shipping Over $250 Secure Ordering 14-Day Returns Analytical Verification Each Certificate of Analysis (COA) is the independent laboratory report for one production lot it records the batch number, the measured purity, and the date of analysis, published against the exact product it belongs to
Neelakantan H, et al
These medications are called GLP-1s (or glucagon-like peptide 1) because they mimic our bodys natural GLP-1 hormone, which plays a key role in blood sugar management and appetite
Semaglutide is mainly an anti-diabetic and secondarily an anti-obesity medication
Glossary of Key Terms KLOW Branded designation for a four-component research peptide blend containing BPC-157 (50mg), TB-500 (10mg), KPV (10mg), and GHK-Cu (10mg) in a 3mL lyophilized vial
US$ 27.87
US$ 22.59
US$ 20.46
US$ 24.90
